NCT03399110
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
레지스트리 요약
- 진행 상태
- 완료 (COMPLETED)
- 질환/조건
- Gastric Cancer
- 시험 유형
- 중재 연구 (INTERVENTIONAL)
- 단계
- Phase 3
- 목적
- 치료
- 중재 유형
- 약물
- 개입·치료
- Oxaliplatin, Capecitabine
- Lead Sponsor
- Fudan University (기타)
캐시 시각: 2026-08-25 18:18:42
요약
Our study aims to compare 4 months versus 6 months of adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in patients with gastric cancer.
Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
Hypothesis: We hypothesize that a 4-month regimen of capecitabine plus oxaliplatin is noninferior to a 6-month regimen with respect to DFS and is associated with lower treatment-related toxicity.
카카오 로그인 후 의뢰